Journals
.jpg)
.jpg)
IACM-Bulletin of 14 July 2013
- Science/Human: Cannabis may decrease symptom severity of opiate withdrawal during methadone maintenance treatment
- Science/Human: Cannabis use does not accelerate progression of liver disease in people with hepatitis C according to a longitudinal study
- News in brief
- A glimpse @ the past
Science/Human: Cannabis may decrease symptom severity of opiate withdrawal during methadone maintenance treatment
A new study suggests that symptoms of opiate withdrawal decrease in patients undergoing methadone maintenance treatment, who use cannabis. The study with 91 patients has been conducted by researches of the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia, USA. Patterns of cannabis use prior to and during methadone maintenance treatment (MMT) were examined to assess possible cannabis-related effects on MMT, particularly during methadone stabilization.
Rates of cannabis use were high during methadone induction, dropping significantly following dose stabilization. History of cannabis use correlated with cannabis use during MMT but did not negatively impact the methadone induction process. Authors noted that “pilot data also suggested that objective ratings of opiate withdrawal decrease in MMT patients using cannabis during stabilization.”
Science/Human: Cannabis use does not accelerate progression of liver disease in people with hepatitis C according to a longitudinal study
In a prospective study with 690 people positive for HIV and hepatitis C virus (HCV) the use of cannabis did not accelerate progression to significant liver fibrosis. The study was conducted at the Department of Epidemiology, Biostatistics and Occupational Health of McGill University in Montreal, Canada. Researchers assessed the association between the average number of cannabis cigarettes smoked per week and progression to significant liver fibrosis, cirrhosis or end-stage liver disease. At baseline, 53% had smoked cannabis in the past 6 months, consuming a median of 7 joints per week (range: 1-21); 40% smoked daily.
They found no evidence for an association between cannabis smoking and significant liver fibrosis progression in HIV/HCV coinfection. Each 10 additional joints per week smoked slightly increased the risk of progression to a clinical diagnosis of cirrhosis and end-stage liver disease (hazard ratio: 1.13). However, when exposure was lagged to 6-12 months before the diagnosis, cannabis was no longer associated with clinical disease progression. This suggests “that reverse causation due to self-medication could explain previous results,” authors wrote. Smaller previous studies had found an association between cannabis use and progression to liver fibrosis in patients with hepatitis C.
News in brief
Holland: Medicinal Cannabis Masterclass
Bedrocan BV is offering its 3rd Medicinal Cannabis Masterclass, September 22-25 in Wageningen, the Netherlands. Scheduled to coincide with the IACM's 7th Conference on Cannabinoids in Medicine (Sept. 27-28 in Cologne, Germany), the course is 3.5 days of comprehensive instruction on the pharmaceutical application of herbal cannabis as regulated by the Dutch Ministry of Health, Welfare, and Sport. Organized by Dr. Arno Hazekamp (Bedrocan), speakers include Dr. Mark Ware, Dr. Jon Page, Dr. Jahan Marcu, and others. The course is capped at 12 participants. Deadline to apply is August 1.
Information on Cannabis Masterclass
Science/Human: The risks of cannabis smoking for the lungs are much lower than that of tobacco smoking
According to a review by Dr. Donald Tashkin, a professor at the University of California in Los Angeles “the accumulated weight of evidence implies far lower risks for pulmonary complications of even regular heavy use of marijuana compared with the grave pulmonary consequences of tobacco.” Smoking cannabis may be associated with chronic bronchitis, but studies do not substantiate claims that it is positively associated with the development of lung cancer, chronic obstructive pulmonary disease (COPD), or emphysema.
University of California at Los Angeles, USA.
Tashkin DP. Ann Am Thorac Soc 2013;10(3):239-47.
Italy: Sativex now available
GW Pharmaceuticals announced that their cannabis spray Sativex is now available in Italy as a prescription medicine for use in the treatment of spasticity in multiple sclerosis. Sativex is now available in several EURopean countries including the UK, Spain and Germany.
Press release by GW Pharmaceuticals of 8 July 2013
USA: /Mexico: Former Mexican president Fox urges cannabis legalization
Former Mexican President Vicente Fox took his activities to legalize cannabis to San Francisco, joining cannabis advocates to urge the United States and his own country to decriminalize the sale and recreational use of cannabis. Fox met for three hours with the advocates, including Steve DeAngelo, an Oakland-based executive director of California's largest cannabis dispensary, and former Microsoft executive Jamen Shively, who hopes to create a Seattle-based cannabis brand now that Washington state has legalized recreational use.
Reuters of 9 July 2013
Science/Human: Proteins identified, which may be responsible for allergies to cannabis
Several proteins in the cannabis plant were identified, which were thought to be responsible for the allergies to cannabis in 23 patients. Among the putative allergens are several enzymes of the plant.
Centers for Disease Control and Prevention, Morgantown, West Virginia, USA.
Nayak AP, et al. Ann Allergy Asthma Immunol 2013;111(1):32-37.
Science/Cells: Cannabinoids may be useful against transplant rejection
In cell experiments with cannabinoids that act on the CB2 receptor data were collected that “support the potential of this class of compounds as useful therapies to prolong graft survival in transplant patients” by inhibiting T-cells.
Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, USA.
Robinson RH, et al. J Neuroimmune Pharmacol. 2013 Jul 4. [in press]
Science/Human: Reduced dopamine synthesis capacity in cannabis users
Scientists compared dopamine synthesis capacity in 19 regular cannabis users with 19 nonusers. Cannabis users had reduced dopamine synthesis capacity in a certain brain region (striatum). Authors concluded that “chronic cannabis use is associated with reduced dopamine synthesis capacity and question the hypothesis that cannabis increases the risk of psychotic disorders by inducing the same dopaminergic alterations seen in schizophrenia.”
Institute of Clinical Sciences, Hammersmith Hospital, Imperial College London, United Kingdom.
Bloomfield MA, et al. Biol Psychiatry. 2013 Jun 29. [in press]
Science/Human: Endocannabinoids influence blood clotting
The endocannabinoids 2-AG and virodhamine induced platelet aggregation, while anandamide was inactive. This effect was independent of cannabinoid receptors. Authors concluded that “pharmacological CB1- and CB2-receptor ligands will not affect platelets and platelet-dependent progression and complications of cardiovascular diseases.”
Institute for Prevention of Cardiovascular Diseases, Ludwig Maximilians University of Munich, Germany.
Brantl SA, et al. Platelets. 2013 Jun 21. [in press]
Science/Cells: Cannabinoids induce death of pancreatic cancer cells
Cannabinoids, which bind to the CB1 and the CB2 receptor impaired the production of energy of pancreatic cancer cells and this resulted “in a strong induction of autophagy [cell degradation] and in the inhibition of cell growth.”
Department of Life and Reproduction Sciences, University of Verona, Italy.
Dando I, et al. Cell Death Dis. 2013 Jun 13. [in press]
Free full text
A glimpse @ the past
One year ago
Two years ago
Online Events 2020
Please find all information of IACM Online Events including free videos of the webinars here.
Conference 2022
The 12th IACM Conference on Cannabinoids in Medicine will be we be held on 20 and 21 October 2022 together with the Swiss SSCM in Basel/Switzerland.
Members only
Regular members can sign up for the new member area of the IACM to access exclusive content.
You need to become a regular member of the IACM to access the new member area.
IACM on Twitter
Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.